Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients

doi:10.1097/QAI.0000000000002589

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23518

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23518

Title:	Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients
Authors:	Huang, YS;Cheng, CY;Liou, BH;Lu, PL;Cheng, SH;Lee, YT;Liu, CE;Sun, HY;Yang, CJ;Tang, HJ;Lin, SP;Ho, MW;Huang, SH;Tsai, HC;Lee, CH;Hung, CC
Keywords:	hepatitis B;antiretroviral therapy;proteinuria;bone mineral density
Date:	2021
Issue Date:	2022-08-05T09:38:34Z (UTC)
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
ISSN:	1525-4135
Abstract:	Background: The efficacy and safety of switching from tenofovir disoproxil fumarate-based antiretroviral therapy to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has not been widely investigated in HIV/hepatitis B virus (HBV)-coinfected Asian population. Methods: Between February and October 2018, HIV/HBV-coinfected patients who had achieved HIV viral suppression with tenofovir disoproxil fumarate-containing regimens were switched to E/C/F/TAF. Assessments of plasma HBV and HIV viral load, HBV serology, renal function, lipid profiles, and bone mineral density (BMD) were performed at weeks 24 and 48 after switch. Results: A total of 274 HIV/HBV-coinfected participants were enrolled, with 12.8% testing HBeAg-positive and 94.2% having plasma HBV DNA <20 IU/mL at baseline. At weeks 24 and 48, 92.7% and 89.8% achieved plasma HBV DNA <20 IU/mL; 4.7% and 5.1% had HBV DNA >= 20 IU/mL; and 2.6% and 5.1% had no data, respectively. At weeks 24 and 48, 95.6% and 94.2% of participants maintained HIV RNA <50 copies/mL, respectively. Compared with baseline, the median urine beta 2-microglobulin-to-creatinine ratio at week 48 decreased significantly from 165 to 90 mu g/g (P < 0.001). The mean BMD of the spine and hip improved at week 48 (+1.77% and +1.33%, respectively). Significantly higher lipid profiles were observed after switch to E/C/F/TAF. Thirteen (4.7%) patients withdrew from the study before week 48, with 7 (2.6%) patients because of adverse effects. Conclusions: Switch to E/C/F/TAF maintained HBV and HIV viral suppression and resulted in the improvement of proteinuria and BMD of the spine and hip but increased lipid levels in HIV/HBV-coinfected patients at week 48.
URI:	http://dx.doi.org/10.1097/QAI.0000000000002589 https://www.webofscience.com/wos/woscc/full-record/WOS:000656627600018 https://ir.csmu.edu.tw:8080/handle/310902500/23518
Relation:	JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES ,2021,v86,issue 4, P473-481
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	201	View/Open

Loading...